Breaking Finance News

Zacks Investment Research downgraded Blueprint Medicines Corp (NASDAQ:BPMC) to Hold in a report released today.

Showing a price of $28.06, Blueprint Medicines Corp (NASDAQ:BPMC) traded 0.29% higher on the day. The last stock price is up 39.32% from the 200-day average, compared with the S&P 500 Index which has fallen -0.01% over the same time. BPMC has logged a 50-day moving average of $25.38 and 200-day average of $20.16. 676,074 shares of Blueprint Medicines Corp were exchanged, up from ann average trading volume of 186,497

Zacks Investment Research has downgraded Blueprint Medicines Corp(NASDAQ:BPMC) to Hold in a report released 8/18/2016.

Performance Graph:

Blueprint Medicines Corp (NASDAQ:BPMC)

A total of 3 firms have reported on Blueprint Medicines Corp. One firm rate the stock a strong buy, two analysts rate the stock a buy, one analyst rate the company a hold, 0 rate the company to underperform, and finally 0 brokeragesrate the company as sell with a 12-month target price of $31.00

Blueprint Medicines Corp has a 52 week low of $13.04 and a one-year high of $31.94. BPMC’s total market value is presently $0.0.

Brief Synopsis About Blueprint Medicines Corp (NASDAQ:BPMC)

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options. The Company has developed a small molecule drug pipeline in cancer and a genetic disease. The Company’s drug candidate, BLU-285, targets KIT Exon 17 mutants and PDGFRa D842V, which are abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. It is engaged in developing BLU-285 for patients with systemic mastocytosis (SM), a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor (GIST). Its drug candidate, BLU-554, targets FGFR4, and a kinase that is aberrantly activated and is a driver of disease in a defined subset of patients with hepatocellular carcinoma (HCC).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.